{"id":"bretzri","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-28T03:58:04.754Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_claudeStub":{"ts":1779138926,"model":"claude-sonnet-4-5-20250929"},"biosimilars":[],"competitors":[],"description":"Bretzri is an investigational therapeutic currently in Phase 2 clinical development at the University of Miami. Limited public information is available regarding its molecular target, mechanism of action, or specific therapeutic indication at this stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05607719","phase":"PHASE2","title":"Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-04-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Bretzri","genericName":"Bretzri","companyName":"University of Miami","companyId":"university-of-miami","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}